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Abstract: The article describes a two-step synthesis of diastereomeric 3-hydroxy-2-
methyl-3-(4-biphenylyl)butanoic acids. In the first step an intermediate α-bromo propanoic 
acid 1-ethoxyethyl ester was synthesized. The second step is a new modified Reformatsky 
reaction in presence of Zn in tetrahydrofuran (THF) at –5 to 10 °C between the previously 
synthesized intermediate and 4-acetylbiphenyl. Synthesis of the other studied β-hydroxy-β-
arylpropanoic acids has already been reported. These β-hydroxy-β-arylpropanoic acids 
belong to the arylpropanoic acid class of compounds, structurally similar to the NSAIDs 
such as ibuprofen. The anti-inflammatory activity and gastric tolerability of the 
synthesized compounds were evaluated. Molecular docking experiments were carried out 
to identify potential COX-2 inhibitors among the β-hydroxy-β-aryl-alkanoic acids class. 
The results indicate that all compounds possess significant anti-inflammatory activity after 
oral administration and that the compounds 2-(9-(9-hydroxy-fluorenyl))-2-
methylpropanoic acid (5) and 3-hydroxy-3,3-diphenyl-propanoic acid (3) possess the 
strongest anti-inflammatory activity, comparable to that of ibuprofen, a standard NSAID, 
and that none of tested substances or ibuprofen produced any significant gastric lesions.  
Keywords: β-Hydroxy-β-arylalkanoic acids, Reformatsky reaction, anti-inflammatory 
activity, molecular docking simulations, COX-2 selective inhibitor 
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Introduction 
Cyclooxygenases (COX) or prostaglandin endoperoxide synthases (PGHS) are the key enzymes in 
the synthesis of prostaglandins, the main mediators of inflammation, pain and increased body 
temperature (hyperpyrexia). Prostaglandins are formed from their precursor, arachidonic acid. 
Arachidonic acid is cleaved from cell membrane phospholipids by phospholipase A2. COX Convert 
arachidonic acid into unstable endoperoxides PGG2 and PGH2. After that PGG2 and PGH2 are 
metabolized by synthases to primary prostaglandins PGD2, PGE2, PGF2α, TXA2 (tromboxane A2) and 
PGI2 (prostacycline). Prostaglandins (PGs) are the lipid mediators made by most cells in the body 
except by red blood cells and released upon almost any type of chemical or mechanical stimulus [1]. 
The two definitely known isoforms of COX, named COX-1 and COX-2, show distinct expressions 
patterns and distinct biological activities. COX-1 is formed in many different cells to create 
prostaglandins used for basic “housekeeping” messages throughout the body. COX-1 is a 
constitutively expressed protein that is responsible for the physiological production of prostaglandins. 
The COX-1 variant protein, named COX-3, is sensitive to inhibition with paracetamol [2]. COX-2 is 
only formed in special cells and is used for signaling both the pain and inflammation. This isoform is 
also called inducible isoform of enzyme COX [3]. In inflammatory processes COX-2 is overexpressed.  
Non-steroidal anti-inflammatory drugs (NSAIDs) are COX inhibitors and prevent PG synthesis, 
thus exhibiting analgesic, antipyretic and anti-inflammatory actions. However, NSAIDs have a number 
of adverse effects, mainly because of their inhibition of the constitutive isoform of COX. The major 
adverse effects of NSAID are gastrotoxic effects (e.g., damage of gastric mucosa, gastric bleeding and 
gastroduodenal ulcers), increased bleeding tendency and delay of the birth process [1]. Nowadays, 
there are two types of COX inhibitors, nonselective, i.e. both COX-1 and COX-2 inhibitors, and 
predominantly selective COX-2 inhibitors such as the "coxibs". Since selective COX-2 inhibitors fail 
to inhibit constitutive COX-1 isoform, they have no gastrointestinal adverse effects. However, recent 
publications have suggested that COX-2 inhibitors, like rofecoxib and celecoxib, may be 
prothrombotic and increase the risk of myocardial infarction [2]. Consequently, a synthesis of new 
NSAIDs, with potent anti-inflammatory, analgesic and antipyretic action, but with no adverse effects is 
highly desired. 
We have synthesized six β-hydroxy-β-arylalpropanoic acids that are structurally similar to COX 
inhibitors: p-isobutylphenylacetic acid (ibufenac), 4-biphenylacetic acid (felbinac), α-(4-isobutyl-
phenyl)propanoic acid (ibuprofen), α-(6-methoxy-2-naphtyl)propanoic acid (naproxen). By 
introducing the oxo-functionality in the gamma position, with respect to the carboxylic group in 4-(4’-
biphenyl)butanoic acid, an increase in their anti-inflammatory activity (fenbufen) can be noticed. β-
Hydroxy-β-arylalkylpropanoic acids belong to the aryl- or cycloalkylpropanoic acid class of 
compounds, structurally similar to the commercially available NSAIDs. The compounds studied in our 
previous article affected the survival of HeLa cells (Human cervix epithelial adenocarcinoma cells), 
having IC50 values from 62.20 to 182.55 μM/L. Most of the examined compounds did not affect 
proliferation of healthy human peripheral mononuclear cells (PBMC) IC50 > 300 μM/L [4]. In this 
work anti-inflammatory activity and gastric tolerability of the synthesized compounds were evaluated. 
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Results and Discussion 
Synthesis of studied compounds 
 β-Hydroxy-β-arylpropanoic acids were synthesized by the two-step reaction. In the first step α-
bromoalkanoic acid 1-ethoxyethyl esters intermediates were synthesized. The second step involved a 
Reformatsky reaction in tetrahydrofuran (THF) at –5 to 10 °C between the previously synthesized 
intermediates and a suitable aldehyde or ketone in the presence of Zn (Scheme 1). The syntheses and 
antiproliferative activity of some β-hydroxy-β-arylalkanoic acids were previously reported [4]. The 
synthesis of 3-hydroxy-2-methyl-3-(4-diphenylyl)butanoic acid (6) has not yet been reported. This 
acid was prepared by the general method described above and fully characterized. The resulting 
mixture of diastereomers was not separated. We observed a single spot on TLC, and assumed to have 
obtained a threo isomer, which has the optimal geometry containing an intramolecular hydrogen bond 
and the most distant methyl groups. 
 
Scheme 1. Synthetic sequence of 3-hydroxy-2-methyl-3-(4-diphenylyl)butanoic acid. 
  
Br
COOH
O+
C6H6
O
O
O
Br
O
O
O
Br
O
+
Zn,THF
0 C°
OZnBr O
O
O
OZnBr O
O
O
H3O+
OH O
OH
 
 
In this work six β-hydroxy-β-propanoic acids (Figure 1) were evaluated for their anti-inflammatory 
activity: 
3-hydroxy-3-(4-isobutylphenyl)butanoic acid (1), 
3-hydroxy-2,2-dimethyl-3-phenylbutanoic acid (2), 
3-hydroxy-3,3-diphenylpropanoic acid (3), 
3-hydroxy-2,2-dimethyl-3-phenylpropanoic acid (4), 
2-(9-(9-hydroxyfluorenyl))-2-methylpropanoic acid (5) and 
3-hydroxy-2-methyl-3-(4-diphenylyl)butanoic acid (6). 
Molecules 2008, 13                    
 
 
606
Figure 1. Structures of the studied compounds. 
OH
COOH
OH
COOH
OH
COOH
HO COOH
COOH
OH
COOH
OH
1 3
4 5 6
2
 
Molecular docking experiments were carried out to identify potential COX-2 inhibitors among the 
β-hydroxy-β-arylapropanoic acid class. The resulting lead compounds were tested for their anti-
inflammatory property in male Wistar rats, weighing 200-250 g, following carrageenan-induced 
oedema. In addition, compounds were evaluated for their gastric response.  
Anti-inflammatory activity: carrageenan-induced paw-oedema  
Results showed that all compounds produced significant anti-inflammatory effect, and like that of 
ibuprofen, were dose-dependent. ED50 values were calculated for ibuprofen and all compounds (Table 
1). Compounds 5 and 3 exhibit strongest anti-inflammatory activity, while compound 4 exhibits the 
least anti-inflammatory effect in whole set. Dose dependence of anti-inflammatory effect of studied 
compounds could be seen on Figure 2. 
 
Figure 2. Dose dependence of anti-inflammatory effects of the studied compounds listed 
in the legend. 
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Gastric tolerability 
 
None of tested substances or ibuprofen produced any significant gastric lesions. The changes 
observed were in range of 0-1 according to the Adami’s scoring scale. Namely, only slight hyperaemia 
or few petechiae were registered in rat stomach regardless of given dose.  
Molecular docking experiments  
 To identify potential anti-inflammatory lead compounds among compounds 1-6, docking 
calculations were performed using Autodock v4.0.1 [4] into the 3D structure of the catalytic site of 
COX-2 enzyme (pdb code: 1cx2) and COX-1 enzyme (pdb code: 1eqg). 
It should be mentioned that the Lamarckian genetic algorithm implemented in Autodock has been 
successfully employed to dock inhibitors into the catalytic site of the COX isoenzymes and correlate 
the obtained binding free energies with inhibitory activities of compounds. Briefly, we carried out 
comparative docking experiments of synthesized compounds 1-6 with the known non-selective COX 
inhibitor ibuprofen. The obtained results were evaluated in terms of binding energy and docking 
positioning into the catalytic site of COX-2. Docking calculations predicted the binding conformation 
of SC-558 for COX-2 isoenzyme and binding conformation of ibuprofen for COX-1 isoenzyme with a 
root main square deviation (RMSD) of 1.44 Δ and 1.48 Δ, respectively, with respect to conformations 
from X-ray crystallographic studies [5].  
Structures of all possible stereoisomer forms of ligands were generated using the ChemOffice v7.0 
Ultra software package and have been MM2 optimized [6]. Each docking experiment consisted of 10 
docking runs with 150 individuals and 500,000 energy evaluations. Other parameters were left to their 
default values. The search was conducted in a grid of 40 points per dimension and a step size of 0.375 
centered on the binding site of enzyme. 
Table 1 shows the binding energies of the top scored solutions found during docking experiments of 
compounds 1-6 and ibuprofen and ED50 values (μM/Kg) obtained in the carrageenan-induced rat paw 
oedema test. In this Table, the result for SC-558 was not included, because of its markedly different 
structure and the lack of a biological assay for it. 
All synthesized compounds display improved binding energies compared to the active ibuprofen. 
Although, some of synthesized compounds are chiral, differences in binding energies of enantiomers 
are not significant. The carboxylate terminal group of these molecules differs in whether the 
carboxylic acid is free or blocked, and by the presence or absence of an α- and β-methyl group. 
Despite these differences, the carboxylate groups of the inhibitors are essentially superimposable. The 
inhibitor carboxylate participates in a network of polar interactions, which includes salt bridges 
between the inhibitor and Arg-120 and hydrogen bonds between the inhibitors and phenolic hydroxyl 
of Tyr-355 (first anchor site, P1). These amino acid residues together with His 90 and Glu 524 tightly 
lock inhibitors into cyclooxygenase active site [5]. Methyl groups form hydrophobic interactions with 
Ser-353 and Val-349 (< 4 Ǻ). Substituents attached to a phenyl ring placed in β-position in respect to -
COOH of inhibitors (isobutyl group of ibuprofen, second phenyl ring of compounds 3, 5 and 6) lie in 
hydrophobic cleft (second anchor site, P2) that is lined with Leu 352, Tyr 385, Trp 387, Tyr 348, Phe 
518, Gly 526 and Ser 530 residues. 
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Table 1. Binding energies of top scored solutions as resulting from docking experiments, 
and corresponding standard biological response of studied compounds. 
Compound Stereoisomer 
Binding energy 
(kcal/mol) 
ED50 
(μM/Kg)* 
COX-1 COX-2 
Ibuprofen 
R -6.47 -6.21 
51.7 
S -6.74 -6.05 
1 
R -7.70 -7.52 
138.7 
S -7.58 -7.20 
2 
R -6.84 -5.89 
81.3 
S -7.15 -6.34 
3  -7.39 -7.17 50.0 
4 
R -6.58 -6.05 
217.1 
S -6.78 -5.92 
5  -8.18 -7.94 14.2 
6 
R,R -8.59 -8.00 
70.1** 
S,S -8.61 -8.35 
R,S -9.02 -8.38 
S,R -8.69 -8.57 
*Result obtained for a mixture of enantiomers. 
**Result obtained for a mixture of diastereomers. 
 
Figure 3. Superimposition of most favorable conformations of compounds 1 (blue), 2 
(green), 4 (gray), 6 (black), and ibuprofen (red) docked into binding site of COX-2 
receptor. This image was created using AutoDockTools 1.4.5. 
 
Molecules 2008, 13                    
 
 
609
This cleft is to some extent larger then above-mentioned ligands; so less voluminous ligands, which 
haven’t substituents on primary phenyl ring (like compounds 2 and 4, Figure 3), do not form van der 
Waals contacts with side chains of above mentioned amino acid residues. The atoms in the middle part 
of the tested molecules do not have contact with any protein atoms.  
 
Figure 4. Superimposition of most favourable conformations of compounds 3 (green), 5 
(blue), and ibuprofen (red) docked into binding site of COX-2 receptor. This image was 
created using AutoDockTools 1.4.5. 
 
 
Atoms in compounds 3, 5, and 6 that are most distant from carboxylic group form hydrophobic 
interactions with Tyr-385 and Ser-530 (< 4 Ǻ) in an extremely hydrophobic environment. Compounds 
3 and 5 interact with the third anchor site, P3 that can clearly be identified through interactions of 
either a single phenyl ring of compound 3, or a single phenyl ring of compound 5, with residues His-
90, Arg- 513 and Gln-192 (< 5 Ǻ) by forming π→cation interactions (Figure 4). 
 
Figure 5. Anchor sites of COX/2 receptors and best docking poses of compounds 1 
(green), 2 (blue), 3 (pink), 4 (gray), 5 (orange), 6 (purple) and ibuprofen (yellow). This 
picture was made using AutoDockTools 1.4.5 
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The P1 anchor site is essential for anti-inflammatory activity. This activity was enhanced by 
interaction with P2 anchor site. Compounds 3 and 5 as the most potent anti-inflammatories have 
additional interactions with P3 anchor site like COX-2 selective inhibitors [7] (Figure 5).  
The bioavailability of compounds 1-6 was assessed using ADME (adsorption, distribution, 
metabolism elimination) [8]. In particular, we calculated the compliance of compounds to the 
Lipinski΄s rule-of-five (Table 2). Briefly, this rule is based on the observation that most orally 
administered drugs have a molecular weight (MW) of 500 or less, a log P no higher than 5, five or 
fewer hydrogen bond donor sites and 10 or fewer hydrogen bond acceptor sites (N and O atoms) [9]. 
In addition, we calculated (by using software MarvinSketch [10]) the polar surface area (PSA) by 
using method, termed topological PSA (TPSA), based on the summation of tabulated surface 
contributions of polar fragments. This descriptor was shown to correlate well with passive molecular 
transport through membranes and, therefore, allows prediction of transport properties of drugs and has 
been linked to drug bioavailability [11]. Thus, passively absorbed molecules with a PSA ›140 Ǻ are 
thought to have low oral bioavailabilities [12,14].  
 
Table 2. Compliance of compounds to computational parameters of bioavailability. 
Compound      No. of Rule-of-five violations      TPSA (Ǻ) at pH 7.4 
Ibuprofen                 0                         40.13  
Compounds:  
  1,2,3,4,5 and 6             0                         60.36  
 
 
On the basis of docking results (Table 1) and bioavailability scores we expected all compounds to 
have a marked anti-inflammatory activity, and they were subjected to in vivo tests.  
 
Structure-activity relationship 
 
From Table 1 could be seen that variations in stereochemistry do not markedly affect the binding 
energy of agent and receptor. Therefore, we looked for a simpler descriptor for the prediction of 
biological activity for this class of compounds. 
We found that extent of the substitution of β-hydroxy propanoic acids on C2 and C3 correlates 
reasonably well with log ED50 as presented on Table 3 and Figure 4. The substitution burden is 
accounted to be twice bigger for phenyl substituent in relation to methyl substituent. In the third 
column of Table 3 is given an index variable describing substitution burden relative to compound 1. 
Regression coefficient for the correlation of compounds 1-6 is 0.784. Ibuprofen nicely fits into this 
correlation with attributed substitution burden 2, which intuitively seems very reasonable one. 
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Table 3. Index variable for the substitution burden for compounds 1 to 6. 
 
 
 
 
 
 
 
 
Figure 4. Correlation of biological response and extent of α− and β-substitution of β-
hydroxy propanoic acids. 
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Conclusions  
Molecular docking calculations accompanied by in vivo biological assay were used to identify 
potential anti-inflammatory agents among the β-hydroxy-β-propanoic acid class of compounds acting 
through a COX-2 inhibition mechanism. The obtained results indicate that all compounds possess 
significant anti-inflammatory activity after oral administration and that compounds 5 and 3 possess the 
Compound log ED50 
Relative 
extent of 
substitution 
Ibuprofen 1.412 2 
1 2.142 0 
2 1.910 2 
3 1.699 1 
4 2.337 1 
5 1.152 3 
6 1.846 1 
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strongest anti-inflammatory activity comparable to that of ibuprofen, a standard NSAID. Tested 
substances or ibuprofen did not exhibit any significant gastric lesions.  
 
Experimental 
 
General 
  
IR Spectra were taken in KBR pellets on Perkin-Elmer 1725 spectrophotometer. 1H- and 13C- 
nuclear magnetic resonance (NMR) spectra were recorded at 200/50 MHz in CDCl3 with tetramethyl-
silane (TMS) as internal standard on a Varian Gemini 200 spectrometer. The mass spectra were taken 
on a Finnigan-MAT 8230 BE MS, employing both chemical ionization (i-C4H10) (CI), and electron 
impact (70 eV) (EI). The elemental analyses were done on Elemetar-Vario EL III equipment. Melting 
points were determined in open capillary tubes on Büchi apparatus and are uncorrected. 
 
Synthesis of 3-Hydroxy-2-methyl-3-(4-biphenylyl)butanoic acid (6) 
 
In a 100 mL two-necked round-bottomed flask equipped with a CaCl2 tube, argon inlet and 
magnetic stirrer, were placed the α-bromopropanoic acid (0.03 mol), ethyl vinyl ether (3.37 g, 5.00 
mL, ˜0.05 mol) and dry benzene (4-6 mL), and the mixture was stirred at room temperature for 2 hours. 
After the evaporation of benzene and excess of ethyl vinyl ether, the residue was distilled under the 
reduced pressure. In this way 4.5 g (0.02 mol) of 1-ethoxyethyl-2-bromopropanoate were obtained.  
In 100 mL three-necked, round-bottomed flask, equipped with a CaCl2 tube, argon inlet and 
magnetic stirrer, Zn (0.02 mol, 1.30 g), 4-acetylbiphenyl (0.013 mol, 2.54 g), dried THF (40 mL) and 
small amounts of HgCl2 and I2 were placed. The previously prepared ester (0.02 mol, 4.5 g) was added 
from a dropping funnel during 30 min under the argon atmosphere. The reaction mixture was cooled in 
an ice bath and constantly magnetically stirred, until all the Zn had disappeared (3 days). The THF was 
removed under reduced pressure followed by addition of benzene (30 mL) and cold 3M HCl (10 mL). 
This reaction mixture was cooled at 0 °C in ice bath, and stirred for ˜ 3 hours. The organic layers were 
collected. The obtained aqueous solutions were additionally extracted with benzene. The combined 
organic extracts were treated with 10% aqueous KHCO3 until pH˜8 was reached (and the hydroxy acid 
was converted into the corresponding potassium salt). The alkaline aqueous solution was extracted 
with a small amount of ether to remove unreacted ketone. This solution was cooled at 0°C, and cold 
10% HCl was carefully added to pH ˜ 2.5, yielding the β-hydroxy acid as an oil at first, which turned 
into crystals after prolonged storage at low temperature. The acid in this fashion was recrystallized 
from benzene. C17H18O3; Mw = 270.33; Melting point: 146 °C; IR (KBr): ν max (cm-1) 3467 (ν ,-CH-
OH), 3423 (ν ,-C(O)-OH), 1686 (ν , >C=O), 1231 (ν , -C-O-); 1H-NMR (δ): 1.07 (d, J 7.2 Hz; 3 H); 
1.35 (d, J 7.2 Hz; 3 H); 1.55 ( s, 3 H); 1.68 (s, 3 H); 2.93 (q, J 7.2 Hz; 1 H); 3.12 (q, J 7.2 Hz; 1 H); 
7.26-7.63 (m, 9 H); 13C-NMR (δ): 12.56 (-CH(CH3 )-); 26.14 (C(OH)(CH3)-); 29.84 (C(OH)(CH3)-); 
48,41 (CH)(CH3); 49.27 (CH)(CH3); 74.85 (C-OH); 125.27 (o-Ph); 127.01 (o’-Ph); 127.32 (o- and p’-
Ph); 128.34 (m’-Ph); 128.78 (m-Ph); 139.94 (pipso-Ph); 140.54 (Cipso’-Ph); 145.90 (Cipso-Ph); 180,34 
(COOH); MS (CI): 271(M+H)+, 253 (M-18), 197 (M-73); Yield (%): 47; Elemental analysis (%): 
Calcd.: C, 75.53; H, 6.71. Found: C, 75.10; H, 6.30.  
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Animal studies 
Adult male Wistar rats, weighing 200-250g, were used in the carrageenan-induced rat paw oedema 
and the gastric tolerability tests. Experimental groups consisted of 10 animals, each. The animals were 
deprived of food for 18-20 h before the beginning of experiments, with free access to tap water. 
Anti-inflammatory activity: carrageenan-induced rat paw oedema test 
The carrageenan-induced rat paw oedema test was used as an experimental model for screening the 
anti-inflammatory activity according to the modified method of Oyanagui and Sato [15]. The tested 
compounds dissolved in DMSO were administered p.o., throughout the orogastric tube, in doses of 0.5 
mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg and 40 mg/kg. Ibuprofen (2-[4-(2-
methylpropyl)phenyl]propanoic acid), also dissolved in DMSO, was used as a reference, and given in 
the same dose-range. The control animals were given vehicle DMSO in a dose of 1 mL/kg p.o. One 
hour after the oral administration of the compounds tested or ibuprofen, carrageenan-saline solution 
(0.5%) and saline were injected in a volume of 0.1 ml into the plantar surface of the right and left hind 
paw, respectively. Left paw served as the control one (non-inflammed paw). The animals were 
sacrificed 3 hours after the carrageenan and saline injection and paws were cut off for weighing. 
Difference in weight between right and left paw, active drug-treated versus vehicle-treated (control) 
rats, served as an indicator of the anti-inflammatory activity of tested drugs (compounds and 
ibuprofen). The anti-inflammatory effect was calculated using the equation: 
Inflammatory response (%) = 100⋅
k
e  
where k is a difference in the paw weight in the control group, and e is a difference in the paw weight 
in the treated group. On the basis of these results, the corresponding mean effective anti-inflammatory 
doses (ED50) were calculated according to the method of Litchfield and Wilcoxon [16]. Results are 
given in Figure 2. 
Gastric tolerability test 
When animals were sacrificed, their stomach were removed and opened along the greater curvature. 
Lesions were examined under an illuminated magnifier (3x). The intensity of gastric lesions was 
assessed according to a modified scoring system of Adami et al. [17] (0: no lesions; 0.5: slight 
hyperaemia or ≤5 petechiae; 1: ≤5 erosions ≤5 mm in length; 1.5: ≤5 erosions ≤ 5 mm in length and 
many petechiae; 2: 6-10 erosions ≤5 mm in length; 2.5: 1-5 erosions >5 mm in length; 3: 5-10 erosions 
>5 mm in length; 3.5: >10 erosions >5 mm in length; 4: 1-3 erosions ≤5 mm in length and 0.5-1 mm in 
width; 4.5: 4-5 erosions ≤5 mm in length and 0.5-1 mm in width; 5: 1-3 erosions >5 mm in length and 
0.5-1 mm in width; 6: 4 or 5 grade 5 lesions; 7: ≥6 grade 5 lesions; 8: complete lesion of the mucosa 
with haemorrhage). 
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Statistical analysis 
Results were expressed as means ± standard deviations (SD). Statistical analysis was done by the 
Mann–Whitney U-test and ANOVA. Differences were accepted as statistically significant when P < 
0.05. 
 
Acknowledgements 
 
Authors are grateful to colleagues: Mr Branko Drakulić and Maja Vitorović for helpful discussions 
and aid in synthetic part of the work. This work is supported by Serbian Ministry of Science, Grants № 
142010. and 142072. 
 
References and Notes 
 
1. Botting, R. M. Cyclooxygenase: Past, present and future. A tribute to John R. Vane (1027-2004). 
J. Therm. Bio. 2006, 31, 208-219. 
2. Kiefer, W.; Dannhardt, G. Novel Insights and Therapeutical Applications in the Field of Inhibitors 
of COX-2. Curr. Med. Chem. 2004, 11, 3147-3161. 
3. Goodsell, D. S. The Molecular Perspective: Cyclooxygenase-2. Oncologist 2000, 5, 169-171. 
4. Dilber, S.P.; Žižak, Ž.S.; Stojković, T.P.; Juranić, Z.D.; Drakulić, B.J.; Juranić, I.O. 
Antiproliferative Activity of β-Hydroxy-β-arylalkanoic Acids. Int. J. Mol. Sci. 2007, 8, 214-228. 
5. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. 
Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy 
function. J. Comput. Chem. 1998, 19, 1639-1662. 
6. Selinsky, B. S.; Gupta, K.; Sharkey, K.; Loll, P. J. Structural Analysis of NSAID Binding by 
Prostaglandin H2 Synthase: Time-Dependent and Time-Independent Inhibitors Elicit Identical 
Enzyme Conformations. Biochemistry-US 2001, 40, 5172-5180. 
7. CS ChemOffice Version 7.0 Ultra. Cambridge Soft Corporation, Software Publishers Association: 
Washington D.C., USA. 
8. Rosati, O.; Curini, M.; Marcotullio, M. C.; Macchiarulo, A.; Perfumi, M.; Mattioli, L.; Rismondo, 
F.; Cravotto, G. Synthesis, docking studies and anti-inflammatory activity of 4,5,6,7-tetrahydro-
2H-indazole derivatives. Bioorg. Med. Chem. 2007, 15, 3463-3473. 
9. Smith, D.A.; Van der Waterbeemd, H. Pharmacokinetics and metabolism in early drug discovery. 
Curr. Opin. Chem. Biol. 1999, 3, 373-378. 
10. Lipinski, C.A.; Lombardo, F.; Dominy, B.; Feeney, P. Experimental and computational 
approaches to estimate solubility and permeability in drug discovery and development settings. 
Adv. Drug Deliv. Rev. 2001, 46, 3-26. 
11. PSA plugin, Marvin 4.1.13; ChemAxon (http://www.chemaxon.com), 2007. 
12. Ertl, P.; Rohde, B.; Selzer, P. Fast Calculation of Molecular Polar Surface Area as a Sum of 
Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties. 
J. Med. Chem. 2000, 43, 3714-371. 
Molecules 2008, 13                    
 
 
615
13. Palm, K.; Stenberg P.; Luthman, K.; Artursson, P. Polar molecular surface properties predict the 
intestinal absorption of drugs in humans. Pharm. Res. 1997, 14, 568-571. 
14. Norinder, U.; Osterberg, T.; Artursson, P. Theoretical calculation and prediction of intestinal 
absorption of drugs in humans using MolSurf parameterization and PLS statistics. Eur. J. Pharm. 
Sci. 1999, 8, 49-56. 
15. Oyanagui, Y.; Sato, S. Inhibition by nilvadipine of ischemic and carrageenan paw edema as well 
as of superoxide radical production from neutrophils and xanthine oxidase. Arzneimittel-Forsch. 
1991, 41, 469-474. 
16. Litchfield, J.T.; Wilcoxon, F.A. A simplified method of evaluating dose-effect experiments. J. 
Pharmacol. Exp. Ther. 1949, 96, 99. 
17. Adami, E.; Marazzi-Uberti, E.; Turba, C. Pharmacological research on gefarnate, a new synthetic 
isoprenoid with an anti-ulcer action. Arch. Int. Pharmacodyn. Ther. 1964, 147, 113-145. 
 
Sample Availability: Samples of the compounds 1-6 are available from the authors (contact S.P. 
Dilber; sandad@pharmacy.bg.ac.yu). 
© 2008 by MDPI (http://www.mdpi.org). Reproduction is permitted for noncommercial purposes. 
